Editas Medicine to Participate in Upcoming Investor Conferences
01 sept. 2022 06h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following...
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
03 août 2022 06h29 HE
|
Editas Medicine, Inc.
Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease;...
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
27 juil. 2022 06h30 HE
|
Editas Medicine, Inc.
Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered AsCas12a...
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
26 juil. 2022 06h26 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
20 juil. 2022 16h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly...
Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer
18 juil. 2022 07h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the...
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
07 juin 2022 07h00 HE
|
Editas Medicine, Inc.
TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery...
Editas Medicine Reports Inducement Grants to New Chief Executive Officer
06 juin 2022 16h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly...
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
18 mai 2022 06h45 HE
|
Editas Medicine, Inc.
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo...
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
12 mai 2022 16h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA)...